Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8810
Title: Open, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study
Authors: Eskiyurt, Nurten
İrdesel, Jale
Sepici, Vesile
Uğurlu, Hatice
Kirazlı, Yeşim
Ardıç, Füsun
Bütün, Bülent
Akyüz, Gülseren
Cerrahoğlu, Lale
Şendur, Ömer Faruk
Keywords: Bisphosphonate
Ibandronate
Patient preference
Postmenopausal osteoporosis
alendronic acid
angiotensin II antagonist
anilide
beta adrenergic receptor blocking agent
calcium
dihydropyridine derivative
dipeptidyl carboxypeptidase inhibitor
diuretic agent
hydroxymethylglutaryl coenzyme A reductase inhibitor
ibandronic acid
risedronic acid
salicylic acid
salicylic acid derivative
serotonin uptake inhibitor
vitamin D
vitamin D derivative
abdominal pain
adult
aged
article
Candidate Identification Questionnaire
connective tissue disease
drug efficacy
drug intoxication
drug safety
drug substitution
drug tolerability
drug withdrawal
dyspepsia
female
gastrointestinal disease
gastrointestinal symptom
hernia
human
infection
infestation
injury
lung embolism
major clinical study
metabolic disorder
multicenter study
musculoskeletal disease
nausea
nutritional disorder
open study
Osteoporosis Patient Satisfaction Questionnaire
patient compliance
patient preference
patient satisfaction
postmenopause osteoporosis
prospective study
quality of life
questionnaire
scoring system
screening test
stomach upset
treatment duration
treatment outcome
Turkey (republic)
Publisher: Galenos Yayincilik,
Abstract: Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (?80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.
URI: https://hdl.handle.net/11499/8810
https://doi.org/10.4274/tod.29491
ISSN: 2146-3816
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
aeaa33cc-5274-4071-8353-c63113733bff.pdf593.14 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

1
checked on Nov 21, 2024

Page view(s)

46
checked on Aug 24, 2024

Download(s)

22
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.